Exploring the convergence of gene editing and RNAi in iPSC-derived allogeneic cell therapy

  • Published on 20th November 2023 by Laverock Therapeutics
Share

Within cell and gene therapy, there is a growing reliance on innovation in genome editing technology. David McCall (Senior Editor, BioInsights), speaks to Vlad Seitan, (Chief Scientific Officer, Laverock Therapeutics) about enhancing advanced therapies through a novel approach that combines the power of gene editing with the RNA interference (RNAi) pathway.

In a recent interview with BioInsights, Vlad Seitan discusses Laverock's ambitions to engineer improved cell and gene therapies through GEiGS®, the company’s new gene silencing technology. Vlad explains more about gene editing, its relationship with RNAi, and the way GEiGS technology works to repurpose endogenous miRNA genes and channel their silencing activity towards new targets of interest.

The full article can be viewed on the BioInsights website here.

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.